Commonwealth Equity Services LLC Has $4.25 Million Holdings in Hims & Hers Health, Inc. $HIMS

Commonwealth Equity Services LLC grew its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 31.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 130,785 shares of the company’s stock after purchasing an additional 30,933 shares during the period. Commonwealth Equity Services LLC’s holdings in Hims & Hers Health were worth $4,247,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Binnacle Investments Inc bought a new stake in Hims & Hers Health during the 3rd quarter worth about $28,000. Silicon Valley Capital Partners bought a new stake in Hims & Hers Health during the 3rd quarter worth about $48,000. Flagship Harbor Advisors LLC bought a new stake in Hims & Hers Health during the 4th quarter worth about $28,000. Bogart Wealth LLC lifted its position in Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after buying an additional 632 shares in the last quarter. Finally, Smartleaf Asset Management LLC boosted its position in Hims & Hers Health by 44.7% during the third quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock valued at $54,000 after purchasing an additional 283 shares during the last quarter. 63.52% of the stock is owned by institutional investors.

Insider Activity at Hims & Hers Health

In other news, COO Michael Chi sold 97,289 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total value of $2,402,065.41. Following the transaction, the chief operating officer owned 407,282 shares of the company’s stock, valued at approximately $10,055,792.58. This represents a 19.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Oluyemi Okupe sold 7,950 shares of the company’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $23.64, for a total value of $187,938.00. Following the completion of the transaction, the chief financial officer directly owned 262,954 shares in the company, valued at $6,216,232.56. The trade was a 2.93% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 212,807 shares of company stock worth $5,473,644. 11.76% of the stock is currently owned by corporate insiders.

Hims & Hers Health Price Performance

NYSE:HIMS opened at $26.25 on Monday. The stock’s 50 day moving average price is $24.61 and its two-hundred day moving average price is $27.02. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43. The firm has a market capitalization of $6.08 billion, a price-to-earnings ratio of -291.71, a P/E/G ratio of 49.14 and a beta of 2.37. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The business had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. During the same period in the prior year, the business earned $0.20 EPS. The company’s revenue for the quarter was up 3.8% compared to the same quarter last year. On average, analysts anticipate that Hims & Hers Health, Inc. will post 0.04 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Leerink Partners increased their price target on Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a research report on Monday, March 16th. Morgan Stanley reduced their price target on Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 24th. Truist Financial raised their target price on shares of Hims & Hers Health from $18.00 to $23.00 and gave the company a “hold” rating in a research note on Friday, May 22nd. Needham & Company LLC raised their target price on shares of Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Finally, Jefferies Financial Group set a $24.50 target price on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Four investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $28.70.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.